Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-

Liquidia Technologies (LQDA) PT Lowered to $23 at Jefferies

May 14, 2024 4:17 PM EDT

Jefferies analyst Kambiz Yazdi lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $23.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "Liquidia is prepared to launch and awaits FDA action on Yutrepia's NDA. Co remains active in R&D by... More